Nuwellis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.2M
- Price
- $2.86
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.35%
- Volume
- 98.2K
Quote data as of 7:03 AM ET
About
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Quick stats
Shares outstanding364.3K
Computed float43.9K
Float sourceUnknown
Cash runway (months)-1.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001506492
Websitehttps://www.nuwellis.com
AI Summary
AI-generated15d agostandardbullishexecutive changeIncoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
Incoming CEO Mike McCormick outlined strategic priorities effective June 30 as he assumes the role of Chief Executive Officer, with John Erb transitioning to Chairman of the Board.
The company reported Q1 2026 revenue growth of 26% year-over-year, with gross margin expanding 14 percentage points to 70.1%.
Strategic initiatives include expanding Aquadex pediatric indications to 5kg+ patients and integrating the recently acquired Rendiatech technology.
Red flags
- Company cites maintaining Nasdaq listing as an important strategic component
- Reducing cash burn remains a key priority